

ASX Release

28 October 2022

Cleansing Notice

NOTICE PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT

Anatara Lifesciences Limited (the **Company**) gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**) as follows:

1. The Company has issued 10,703,343 fully paid ordinary shares (**Shares**) in the Company at an issue price of \$0.035 (3.5 cents) per Share under the capital raising announced to the ASX on Friday, 21 October 2022.
2. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
3. As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and
 - (b) Section 674 of the Corporation Act.
4. As at the date of this notice, there is no 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) required to be disclosed under section 708A(6)(e) of the Corporations Act.

For and on behalf of Anatara Lifesciences Limited.



Stephen Denaro
Company Secretary
Anatara Lifesciences Limited

Authorised and approved by the Board of Anatara Lifesciences Limited.

—ENDS—

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd, North Melbourne, VIC 3051, Australia

Email info@anatara.com | Website anataralifesciences.com



For more information please contact:

General inquiries	
David Brookes Chair, Anatara Lifesciences Ltd +61 (0) 411 712 579 dbrookes@anatara.com	Dirk van Dissel Candour Advisory – Investor Relations +61 (0) 408 326 367 dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

